drugset / Trial / NCT00362232

Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.

NCT00362232

Phase 3 Completed 3148 enrolled Bayer
RandomizedParallel-groupTriple-blindPrevention

Summary

The purpose of this study is to assess if 10 mg BAY59-7939, taken once daily as a tablet, is safe and prevents blood clot which may form after a knee replacement operation.

Timeline

Start
2006-06
Primary completion
2007-01
Completion
2008-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Enoxaparin sodium Other / unclassified 30 mg Subcutaneous
Subject Rivaroxaban Other / unclassified 10 mg Oral